Alain Beck

Meet Alain Beck

In addition to his role at Pierre Fabre, Alain Beck is also co-founder and associate editor of mAbs – an open access journal publishing antibody research – and a member of the MabDesign founders’ college. He has been involved in clinical-stage biologics R&D programs for MSD’s dalotuzumab, GSK’s telisotuzumab/lepatinib, and Pierre Fabre’s cetuximab. He is also involved in workshops within the ANSM (France), as well as at the EMA, FDA, NIST, US Pharmacopeia, and the WHO.